Nothing Special   »   [go: up one dir, main page]

Kataoka et al., 2024 - Google Patents

Predictors of dropout from abemaciclib therapy in patients with breast cancer: a multicenter retrospective cohort study

Kataoka et al., 2024

View PDF
Document ID
9003317729609053676
Author
Kataoka N
Hata T
Hosomi K
Hirata A
Ota R
Nishihara M
Kimura K
Iwamoto M
Ashida A
Neo M
Publication year

External Links

Snippet

Objective: This study explored the predictors of dropping out from abemaciclib therapy, a cyclin-dependent kinase 4 and 6 inhibitor, in patients with breast cancer. Material and Methods: Between November 2018 and March 2023, 147 patients with breast cancer treated …
Continue reading at www.researchsquare.com (PDF) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment; Prognosis
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material

Similar Documents

Publication Publication Date Title
Frasor et al. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome
Schummer et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125
Pernar et al. A prospective study of the association between physical activity and risk of prostate cancer defined by clinical features and TMPRSS2: ERG
Go et al. Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B‐cell lymphoma
Gibbs et al. Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer
EP2245460B1 (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
Zhang et al. Prevalence and prognostic value of malnutrition among elderly cancer patients using three scoring systems
Luo et al. PPARα gene is a diagnostic and prognostic biomarker in clear cell renal cell carcinoma by integrated bioinformatics analysis
Sato et al. Predictive value of 3′-deoxy-3′-18F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer
Hara et al. Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma
Hoffmann et al. Increased expression of ido1 is associated with improved survival and increased number of tils in patients with high-grade serous ovarian cancer
Kataoka et al. Predictors of dropout from abemaciclib therapy in patients with breast cancer: a multicenter retrospective cohort study
Fatima et al. Circulatory proteins in women with breast cancer and their chemotherapeutic responses
Zheng et al. Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer
Gunawan et al. The hypoxic response expression as a survival biomarkers in treatment-naive advanced breast cancer
Van Mieghem et al. Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age
Kataoka et al. Predictors of abemaciclib discontinuation in patients with breast cancer: a multicenter retrospective cohort study
Nastoupil et al. P1125: Celestimo: A Phase Iii Trial Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide Versus Rituximab Plus Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma
CN111433375A (en) Method of selecting a treatment for a cancer patient
US20120202888A1 (en) Biomarkers of prostate cancer and predicting mortality
Moffat et al. KRAS Allelic Variants in Biliary Tract Cancers
CN114354931B (en) Application of splenomegaly in determining curative effect of tumor patient immune checkpoint inhibitor treatment
Tutan et al. Role of systemic immune-inflammation index in predicting mortality in cancer patients in palliative care units
Shin et al. Novel predictive models of early death less than 1 year in patients with metastatic renal cell carcinoma after treatment with first-line tyrosine kinase inhibitors
Willis et al. Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite US study